VTRS Q4 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B-1.0% YoY

Gross Profit

$1.6B41.6% margin

Operating Income

-$455M-11.8% margin

Net Income

-$766M-20.0% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-2.7%

Cash Flow

Operating Cash Flow

$479M

Free Cash Flow

$279M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$47.7B

Total Liabilities

$27.2B

Stockholders' Equity

$20.5B

Cash & Equivalents

$992M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.9B	-1.0%
Gross Profit	$1.6B	$1.3B	+25.3%
Operating Income	-$455M	-$201M	-125.8%
Net Income	-$766M	$1.0B	-175.7%

Revenue Segments

Brands

$2.4B56%

Generics

$1.9B44%

Geographic Segments

Developed Markets Segment

$2.3B61%

Emerging Markets Segment

$619M16%

Greater China Segment

$515M13%

Japan, Australia and New Zealand Segment

$372M10%